Olorofim Aspergillus Infection Study (NCT05101187)
Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (140 Sites)
Showing the first 25 of 140 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- City of Hope National Medical Center — Duarte, California
- University of California Davis Health System — Sacramento, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
- University of Florida — Gainesville, Florida
- Augusta University — Augusta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- University of Kansas Medical Center — Kansas City, Kansas
- The Johns Hopkins Hospital — Baltimore, Maryland
- NIH Clinical Center ,NIAID,NIH — Bethesda, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Clairvoyant Research Group, LLC — Las Vegas, Nevada
- Rutgers RWJMS — New Brunswick, New Jersey
- Weill Cornell Medicine NY Presbyterian Hospital — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Duke Department of Medicine Infectious Diseases Division — Durham, North Carolina
- OU Health OU Medical Center — Oklahoma City, Oklahoma
- University of Pittsburgh Medical Center Health System — Pittsburgh, Pennsylvania
- Houston Methodist — Houston, Texas
- Fred Hutchinson Cancer Center — Seattle, Washington
- Royal NorthShore Hospital — Saint Leonards, New South Wales
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Invasive Aspergillosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.